Single-agent neratinib is effective in the treatment of metastatic HER2-positive breast cancer [7–9], including trastuzumab-naïve and trastuzumab-pretreated patients [8], and HER2 mutation-positive breast cancer [10]. The gene discussed is ERBB2; the disease is breast carcinoma.